Aclarion, Inc. (NASDAQ:ACON) Short Interest Up 90.7% in February

Aclarion, Inc. (NASDAQ:ACON) was the recipient of a significant increase in short interest in February. As of February 28th, there was short interest totalling 471,200 shares, an increase of 90.7% from the February 13th total of 247,100 shares. Approximately 93.3% of the company’s stock are sold short. Based on an average daily trading volume, of 3,450,000 shares, the days-to-cover ratio is currently 0.1 days.

Wall Street Analysts Forecast Growth

A number of research analysts have weighed in on ACON shares. Ascendiant Capital Markets cut their price target on shares of Aclarion from $502.50 to $435.50 and set a “buy” rating on the stock in a research note on Wednesday, November 27th. Maxim Group reiterated a “hold” rating on shares of Aclarion in a report on Friday, December 13th.

Aclarion Trading Down 15.9 %

NASDAQ ACON opened at $0.69 on Friday. Aclarion has a 12-month low of $0.65 and a 12-month high of $231.15. The firm’s 50 day moving average is $7.91 and its 200-day moving average is $40.77.

About Aclarion

Aclarion, Inc, a healthcare technology company, leverages for Magnetic Resonance Spectroscopy (MRS) in the United States. It develops NOCISCAN Post-Processor suite of software applications comprising NOCICALC that receives the raw un-processed NOCISCAN MRS exam data and post-processes that raw data into final spectra and performs various degenerative pain biomarker; and NOCIGRAM, a clinical decision support software.